Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency

Baxter International Inc. BAX and Halozyme Therapeutics, Inc. HALO today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin product for use in patients with primary immunodeficiency . The subcutaneous administration is facilitated by recombinant human hyaluronidase, an enzyme that increases dispersion and absorption of the IG. The data confirm the interim results presented late in 2010 and support the recent submission of a biologics license application to the United States Food and Drug Administration.